Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Breast Neoplasms 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9toripalimab 8venetoclax 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7Carboplatin 7pembrolizumab 6irinotecan sucrosofate 6Temozolomide 6HMPL-013 6tislelizumab 5sintilimab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Fluorouracil 5Etoposide 5Cisplatin 5Biopsy 5osimertinib 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × pirfenidone × Clear all
NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Harbin Medical University

Phase 1/2 Not yet recruiting
12 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06484153 2024-07-03

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1/2 Not yet recruiting
25 enrolled
Gastrointestinal

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡